NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: The Scott Partnership
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Thermo Fisher Scientific Webinar Prepares ICP Users for New United States Pharmacopeia - Thermo Fisher Scientific has launched a webinar to prepare ICP users for the new United States Pharmacopeia chapters proposal (NYSE: TMO)
Thermo Fisher Scientific Webinar Prepares ICP Users for New United States Pharmacopeia

 

NewswireToday - /newswire/ - Cambridge, United Kingdom, 2010/07/15 - Thermo Fisher Scientific has launched a webinar to prepare ICP users for the new United States Pharmacopeia chapters proposal (NYSE: TMO).

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Thermo Fisher Scientific, Inc., the world leader in serving science, today announced an informative webinar to help users of inductively coupled plasma (ICP) technologies prepare for the introduction of the proposed United States Pharmacopeia (USP) chapters 232 and 233 on trace elemental impurities in pharmaceutical products. The educational presentation provides the pharmaceutical industry with valuable information about how ICP techniques can facilitate compliance with these emerging legislative requirements. The webinar, entitled “Preparing for the Proposed United States Pharmacopeia Chapters on Trace Elemental Impurities in Pharmaceuticals with ICP Techniques,” is now available to view on-demand.

Presented by Matthew Cassap, senior ICP applications specialist for Thermo Fisher Scientific, the comprehensive webinar discusses the limitations of the current USP method governing the analysis of heavy metals in pharmaceutical products. In addition, the webinar provides a historical background and detailed overview of the proposed new chapters.

The presentation features the Thermo Scientific iCAP 6000 Series ICP spectrometer, demonstrating the efficiency of ICP techniques for the reproducible analysis of trace elemental impurities in pharmaceuticals in compliance with the upcoming regulatory requirements. In addition, Thermo Scientific iTEVA Security Software plays a crucial role in legislative compliance efforts as it allows for optimization of instrument parameters and elimination of interferences, delivering maximum accuracy and reliability of results. The webinar will also discuss other elemental analysis techniques and how these can be utilized for the analysis of trace elemental impurities in pharmaceuticals.

Matthew Cassap comments: “The latest Thermo Scientific webinar is essential for pharmaceutical scientists who need to stay up-to-date with elemental analysis techniques and, in particular, ICP-OES and ICP-MS methodologies in order to meet future legislative requirements in pharmaceutical analysis. The proposed USP chapters mark a new era for the analysis of trace elemental impurities in pharmaceutical products and the industry must get ready for the change. The Thermo Scientific range of ICP-OES and ICP-MS instrumentation enables users to comply with the regulatory additions while delivering accurate and repeatable results.”

Thermo Scientific is part of Thermo Fisher Scientific, the world leader in serving science.

About Thermo Fisher Scientific
Thermo Fisher Scientific, Inc. (thermoscientific.com) is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of more than $10 billion, we have approximately 35,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through two premier brands, Thermo Scientific and Fisher Scientific, which offer a unique combination of continuous technology development and the most convenient purchasing options. Our products and services help accelerate the pace of scientific discovery, and solve analytical challenges ranging from complex research to routine testing to field applications.

For further press information please contact: Celine Callender, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, United Kingdom T: + 44 1477 539 539, F: +44 1477 539 540, E: thermo[.]scottpr.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: The Scott Partnership

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Thermo Fisher Scientific Webinar Prepares ICP Users for New United States Pharmacopeia

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Celine Callender - Scottpr.com 
+44(0)14 7753 9539 analyze[.]thermofisher.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any The Scott Partnership securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From The Scott Partnership / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen Adds Another Program into its Pre-clinical R&D Oncology Pipeline through An Exclusive Worldwide Collaboration with Accent Therapeutics
Evaxion Biotech Lauded by Frost & Sullivan for Helping Develop Highly Targeted Therapies with its AI Immunology Platforms
Kyowa Hakko Acclaimed by Frost & Sullivan for its Non-GMO, Allergen-free, Immune Support Paraprobiotic Ingredient, IMMUSE™
DSM to Acquire First Choice Ingredients to Accelerate Growth in Food and Beverage
STEMCELL Technologies Launches Human Pluripotent Stem Cell Characterization and Banking Services in Partnership with WiCell
Biocon Selects TrackWise to Enable Enterprise Quality Management Across Global Biopharmaceutical Operations
STEMCELL Technologies and Hubrecht Organoid Technology to Partner on Non-Oncology Organoid Drug Screening Services
Ipsen and Exicure Enter into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders
Ipsen Strengthens its Pre-clinical Oncology Pipeline with An Exclusive Worldwide-collaboration with BAKX Therapeutics, Inc. for BKX-001
Pharma and Biotech to Highly Invest in RNA Therapeutics to Expedite Research & Development across the Globe Finds Frost & Sullivan
Parexel Commended by Frost & Sullivan for Developing a Flexible and Agile Delivery Model to Improve Clinical Trial Outcome
Ipsen and IRLAB Enter Exclusive Worldwide Licensing Agreement Aimed to Improve the Lives of People Living with Parkinson’s Disease
Exelixis and Ipsen Announce Cabozantinib in Combination with An Immune Checkpoint Inhibitor Significantly Improved Progression
Ipsen Opts-in to Join Exelixis with Ongoing Development of Cabometyx® for People Living with A Form of Thyroid Cancer
Antibiotic Alternatives Stimulate New Product Development in Global Animal Feed Ingredient Market Finds Frost & Sullivan

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  MONOVERSE USA, Inc.





 
  ©2021 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)